Global Enzymatic Debridement Market By Type (Chronic Wounds, Diabetic Foot Ulcers, Pressure Ulcers, Venous Leg Ulcers, Acute Wounds, Burn, and Other Acute Wounds), By Product (Collagenase Product, Papain Product, and Others), By End-use (Hospitals, Clinics, and Others), Region and Companies – Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2024-2033

Report Overview

Global Enzymatic Debridement Market size is expected to be worth around USD 1,549.2 million by 2033 from 825.3 million in 2023, growing at a CAGR of 6.5% during the forecast period from 2024 to 2033.

Wound debridement is a process of removing dead or necrotic tissue from the wound. These wounds are generally caused due to underlying medical conditions and do not respond to the natural healing response of the immune system. This necessitates an external debridement to remove the dead tissues, and temporary reconstruction of tissue walls, to help the body heal.

Patients suffering from pressure ulcers, gangrene, and chronic conditions are widely treated with enzymatic debridement by providing as their wound conditions are highly sensitive. In enzymatic debridement, enzymes such as papain, collagenase, and bromelain are externally introduced to the wound through the topical application.

The increasing demand for advanced wound care solutions and the rising global burden of chronic wounds are anticipated to drive the global enzymatic debridement market during the projection period. In conditions such as gangrene or pressure ulcer wounds, certain areas of wounds become sensitive to surgical equipment.

In such cases, enzymatic debridement is performed as it topically suspends the proteolytic enzymes on the wounds, which contain necrophilic enzymes that naturally soften the dead tissue making it remove seamlessly. The rising global incidences of chronic wounds and traumatic wounds are projected to fuel the market in the coming years.

Key Takeaways

• In 2023, the global enzymatic debridement market generated a revenue of 3 million in 2023, with a CAGR of 6.5%, and is expected to reach USD 1,549.2 million by the year 2033.
• The type held a major share of the market, with the chronic wounds segment taking the lead in 2023 with a market share of 3%.
• By product, the collagenase product accounted for a significant share of 4%, owing to the wide availability and biocompatibility of the product.
• By end-use, the hospital among the other sub-segments held a significant revenue share of the market with 3% of the global enzymatic debridement market.
• The North American region led the market by securing a market share of 5% in 2023 owing to the surging adoption of advanced wound care technology in the region.

By Type Analysis

Based on type, the market is divided into chronic wounds, diabetic foot ulcers, pressure ulcers, venous leg ulcers, acute wounds, burns, and other acute wounds. The chronic wounds segment held a dominant share in 2023, with a market share of 73.3% owing to a couple of factors such as the growing number of elderly demographic, the increasing burden of diabetes, and the rising incidences of pressure ulcers, and foot ulcers globally.

Apart from these medical conditions, chronic wounds are also caused due to major accidental injuries such as traumatic injuries caused in road accidents, where victims may have suffered a major thrust, crush wounds, burns, and lacerations, that lead to post-accidental trauma.

In such cases, the patients may have a lot of debris & foreign bodies trapped in wounds along with serious soft tissue damage, which makes their treatments sensitive to surgical equipment. This is where enzymes come in handy to naturally break down the dead or infected tissue. The process also helps to remove debris trapped in wounds, thereby reducing the scope of infection.

The process of autolytic debridement helps stimulate the natural immune response of the body which promotes quicker recovery. Enzymatic debridement also helps surgeons create a wound bed to proceed with surgeries, where wounds can be introduced with skin grafts for closure. The rising incidences of accidental injuries worldwide are anticipated to drive this segment in the coming years.

For instance, according to the report published by the World Health Organization (WHO) on December 13, 2023, about 1.19 million people of the world population die due to road accidents and about 92% of such fatalities occur in low-to-middle-income countries.

By Product Analysis

Based on product, the market is segmented into collagenase products, papain products, and others. Among these, the collagenase product segment held a significant share of 56.4% due to the multifaceted benefits of this product. Collagenase acts as a crucial component in wound care and healing, as it is highly bio-compatible. It is a combination of microbial cells and animal tissues that are accepted by our body, without causing any complications or infections.

It acts as a superior debridement agent which quickly breaks down the collagen-based tissue present in several types of wounds. Collagen shows significant promise in the repairement of damaged tissue and is hence mainly used in working with impaired wounds. The product is versatile and comes in topical gels, wound dressings, and powdered form to cater to a wide range of applications.

As it is an animal-derived product, it is available in abundance and gives ample profit margins for manufacturers. This is why, the players in the market are highly investing in research & development in collagen technology which is expected to create several opportunities for the segment during the forecast period.

By End-use Analysis

The global enzymatic debridement market is segmented based on end-use into hospitals, clinics, and others. The hospital segment held the largest share of the market at 54.3%, owing to the growing prevalence of hospital-acquired wounds such as pressure ulcers and post-surgical trauma. Patients with mobility issues, impairment, and those in coma are mainly found to develop various ulcers over time.

Patients who are bedridden for a prolonged period and those who have limb impairment tend to sit or lie in the same place on a bed or wheelchair. This makes them more susceptible to developing bed sores or ulcers caused due to pressure, that breaks down the outer layer of skin. Physically disabled people may have certain conditions due to which they have muscular spasms, ultimately damaging the epidermis, and thereby causing pressure ulcers.

Such patients are admitted to hospitals for their efficient care facilities, skilled doctors & nursing staff. Hospitals have tie-ups with NGOs or government authorities to help patients who do not have any insurance cover or families.

Hospitals provide 24*7 pharmacies, efficient telehealth & outpatient departments, specialty wards, and intensive care units (ICUs), and follow a holistic approach toward patient care. The hospital facilities are traditionally entrusted by patients to fully recover patients from diseases. Moreover, the increasing advancements in hospital facilities due to the incorporation of AI and IoTs are projected to significantly propel this segment during the projection period.

Key Market Segments

By Type

• Chronic Wounds
• Diabetic Foot Ulcers
• Pressure Ulcers
• Venous Leg Ulcers
• Acute Wounds
• Burn
• Other Acute Wounds

By Product

• Collagenase Product
• Papain Product
• Others

By End-use

• Hospitals
• Clinics
• Others

Drivers

The rising prevalence of chronic wounds among the geriatric population drives the market.

The elderly population is highly susceptible to developing chronic wounds due to their age-related deterioration. Wounds such as diabetic foot, pressure ulcers, and venous leg ulcers are common among elderly people as they are more likely to have underlying cardiovascular diseases (CVDs), diabetes, and obesity.

The declining health or underlying conditions result in slow healing of wounds or cause wound healing impairment. The inability to naturally heal which in turn drives the market. For instance, according to the data published by the National Institute of Health (NIH), chronic wounds are mostly seen in the elderly population and about 3% of the population above age 65 in the US had open wounds on March 1, 2021.

Rapid advancements in wound-care technology boost the market.

Various countries across the globe are investing in the advancement of wound care technology. The main objective of this is to improve the efficacy of wound care products to prevent the reoccurrence of complications in the wound healing process. Novel enzymes are being produced and researched to boost the specificity and sensitivity of the debridement process.

The wound present in the patient’s body is sustained due to the presence of microbes & cellular abnormalities that prevent the wound from healing. Players in the market are using advanced enzyme engineering techniques to increase the potency of topical enzymes to remove infected or necrotic tissue.

Topical agents such as hydrogels contain nanofibers that improve the retention of enzymatic debridement agents and speed up the dissolution of debride tissue. Additionally, the growing need for efficient wound care products to be seamlessly applied by healthcare professionals and caregivers is expected to drive the market in the coming years.

For instance, on January 3, 2023, Convatec, a global leader in medical technology launched ConvaFoam, an advanced foam dressing. The dressing can be used at any stage of the wound-healing process, especially for complicated and stubborn wounds.

Restraints

Rising awareness regarding alternative therapies restrains the market.

Wound care therapies such as surgical debridement, antimicrobial dressing, or mechanical debridement are widely used as alternative treatments to enzymatic debridement. Mechanical debridement is majorly used to treat severe wounds with a significant amount of necrotic tissue. Another common debridement therapy used is the surgical debridement therapy which is mostly used in removing the dead tissue from a patient’s wound with the help of specialty surgical equipment.

It is cheaper comparatively cheaper as it is an invasive approach. The process is performed with the help of trained surgeons. Other methods such as antimicrobial dressing also show significant promise in quick patient recovery. These alternative therapies significantly reduce the necessity of enzymatic debridement which is likely to hamper the market in the coming years.

Opportunities

Increasing demand for non-invasive wound care solutions.

Currently, patients are increasingly preferring quickly recoverable and minimally invasive surgeries. The minimal invasion during surgeries leaves less room for post-surgical trauma, scars, and risk of infections. Diabetic patients are highly susceptible to developing chronic infectious wounds due to the nature of the disease.

Their wounds quickly become severe causing irreversible damage. This is where minimally invasive medical intervention such as enzymatic debridement comes into the picture, as it shows promising results of complete debridement of necrotic tissue and the area of infection.

For instance, according to an article published by the NIH, diabetic ulcers or neuropathic ulcers are mostly formed in a patient’s feet and cause irreversible damage leading to amputation. Such wounds are at a high risk of forming a reoccurrence of infections.

The increasing global of diabetes is thus projected to drive the market in the years to come. For instance, according to the data reported by the IDF Diabetes Atlas in 2021, there were about 537 million adults from across the globe were diagnosed with diabetes whereas, the disease caused about 6.7 million deaths in the years.

Latest Trends

Increasing adoption of combination therapies in wound care treatments is projected to boost the market.

The growing adoption of combination therapies in wound care technology is mainly attributed to the rising trend of personalized healthcare treatments. The personalization of care facilities completely caters to individual requirements of treatment for patients.  Similarly, combination therapies are performed with a holistic healing approach for patients.

Patients can avail of advanced wound therapies and dressings. It consists of tailored pharmacological treatments and includes modern cell therapy & hyperbaric oxygen therapy. Every patient has a unique physical condition and requires a different period for healing. Thus, patients are subject to consuming the appropriate diets which are based on their fitness profiles.

These diets are designed to fulfill the nutritional requirements of patients throughout their healing journey. The unique patient-centric approach of combination therapies drives the market.

Geopolitical Impact Analysis

Global geopolitical factors significantly impacted the enzymatic debridement market dynamics. This is mainly attributed to the rapidly changing international relations among various emerging markets and developed economies.

The recent Russian invasion of Ukraine started a Ukrainian refugee crisis in late 2022. The countries that offered refuge to about 6 million refugees were required to set up efficient wound management facilities. This provided players in the market with the opportunity to provide services by doing tie-ups with the government.

The African Continental Free Trade Area (AfCFTA) that took place in 2018, has opened the door for new opportunities for players in the market to trade with the regional players. Players such as ConvaTec and Smith & Nephew expanded their businesses in the African continents by establishing strategic partnerships with local players and tapping into the untapped region.

Moreover, the US-China trade war in 2020, has made China seek its workforce, production, and outsourcing based in emerging South Asian countries such as Vietnam and Thailand.

Regional Analysis

North America is leading the global enzymatic debridement Market

North America dominated the market with the highest revenue of 392.0 million, commanding a share of 47.5% in 2023. This is attributed to the established healthcare structure in the region. The countries such as the US and Canada are the global leaders in advanced healthcare facilities. The region has a majority of the elderly population which is highly susceptible to or living with chronic diseases.

The increasing prevalence of type two diabetes among adult and geriatric populations in the region is majorly responsible for the growing demand for effective wound care solutions in the region. Major players such as ConvaTec, MediWound, and Smith & Nephew, have a strong presence in the region which drives innovation in the wound care market.

Additionally, the healthcare organizations in the region also provide outpatient facilities for remotely located patients. The increasing demand for advanced healthcare facilities in the region is anticipated to drive the market during the forecast period during the forecast period.

Key Regions and Countries

• North America
  • The US
  • Canada
• Europe
  • Germany
  • France
  • The UK
  • Spain
  • Italy
  • Russia & CIS
  • Rest of Europe
• APAC
  • China
  • Japan
  • South Korea
  • India
  • ASEAN
  • Rest of APAC
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of MEA

Key Players Analysis

The players in the global enzymatic debridement market are continuously driving innovation to thrive in the market. They implement multiple business strategies and heavily invest in research studies to stand out on the competitive ground.

Sanara MedTech Inc., Lohmann & Rauscher, Advancis Medical, and Convatec Inc. are among the major players known for diversified global enzymatic debridement production and supply chain networks. These key players along with other industry participants collectively influence the global enzymatic debridement market’s growth, supply, and demand dynamics.

Top Key Players

• Advancis Medical
• Arobella Medical, LLC
• Braun Melsungen AG
• Coloplast
• Convatec Inc.
• DeRoyal Industries
• EZ Debride (US).
• Integra Lifesciences
• Lohmann & Rauscher
• Mölnlycke Healthcare
• RLS Global
• Sanara MedTech Inc.
• Smith & Nephew
• SOLASCURE Limited
• Other Key Players

Recent Developments

• On November 24, 2022, Advansis Medical stated an innovative use of medical honey as an effective autolytic debridement agent for chronic wounds. This study showed signs of complete recovery in a majority of wounds with the honey dressing.
• In May 2024, Convatec Inc., launched AQUACEL Ag+ Extra, an ultimate dressing for venous ulcers. The company aims to provide an ultimate solution to reduce the global burden of venous ulcers of about 143 million patients.

Report Scope